Twitter Icon Facebook Icon Instagram Icon YouTube Icon

Cytovance enters drug development program with OncoQuest

Oklahoma City-based Cytovance has entered into an antibody manufacturing development program with OncoQuest Inc. to establish a reliable and stable supply of an antibody drug which is used to treat ovarian cancer patients. Cytovance is tasked with establishing a reliable and stable supply of the antibody drug to support anticipated registration clinical studies and future commercial needs. Cytovance recently received three CMO Leadership awards in three categories; quality, reliability and compatibility. CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners.